



Press Release

January 31, 2018

Strides Shasun Limited  
(Formerly Strides Arcolab Limited)  
Strides House, Bannerghatta Road,  
Bangalore – 560076.

---

## Strides Shasun receives USFDA Approval for Piroxicam capsules

Product approval from Oral dosage facility at Bangalore

---

**Bangalore, January 31, 2018,** Strides Shasun Limited today announced that its wholly owned subsidiary Strides Pharma Global Pte. Limited has received approval for ***Piroxicam capsules 10mg and 20mg*** from the United States Food & Drug Administration (US FDA). The product received approval within ten months under the GDUFA regime.

According to IMS data, the US market for ***Piroxicam capsules 10mg and 20mg*** is approximately USD 11 Million. The product will be manufactured at the Company's Oral Dosage Facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.

### **About Piroxicam capsules**

Piroxicam is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity. Piroxicam is indicated for the symptomatic relief of rheumatoid arthritis, osteoarthritis or ankylosing spondylitis.

### **About Strides Shasun**

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at [www.stridesarco.com](http://www.stridesarco.com)

**For further information, please contact:**

<p><u>Strides</u></p> <p>Shashank Sinha, Managing Director +91 80 6784 0335</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: <a href="mailto:investors@stridesshasun.com">investors@stridesshasun.com</a></p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></p> <p>K Priya: +91 9535425418 <a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></p>
---	--